| Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline DL Hershman, C Lacchetti, RH Dworkin, EM Lavoie Smith, J Bleeker, ... J Clin Oncol 32 (18), 1941-1967, 2014 | 1382 | 2014 |
| PI3Kδ inhibition by idelalisib in patients with relapsed indolent lymphoma AK Gopal, BS Kahl, S De Vos, ND Wagner-Johnston, SJ Schuster, ... New England Journal of Medicine 370 (11), 1008-1018, 2014 | 1209 | 2014 |
| Cancer-related fatigue, version 2.2015 AM Berger, K Mooney, A Alvarez-Perez, WS Breitbart, KM Carpenter, ... Journal of the National Comprehensive Cancer Network 13 (8), 1012-1039, 2015 | 832 | 2015 |
| Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110δ, for relapsed/refractory chronic lymphocytic leukemia JR Brown, JC Byrd, SE Coutre, DM Benson, IW Flinn, ... Blood, The Journal of the American Society of Hematology 123 (22), 3390-3397, 2014 | 733 | 2014 |
| Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: ASCO guideline update CL Loprinzi, C Lacchetti, J Bleeker, G Cavaletti, C Chauhan, DL Hertz, ... Journal of Clinical Oncology 38 (28), 3325-3348, 2020 | 573 | 2020 |
| Safety and benefit of discontinuing statin therapy in the setting of advanced, life-limiting illness: a randomized clinical trial JS Kutner, PJ Blatchford, DH Taylor, CS Ritchie, JH Bull, DL Fairclough, ... JAMA internal medicine 175 (5), 691-700, 2015 | 539 | 2015 |
| Dose-adjusted EPOCH-R compared with R-CHOP as frontline therapy for diffuse large B-cell lymphoma: clinical outcomes of the phase III intergroup trial alliance/CALGB 50303 NL Bartlett, WH Wilson, SH Jung, ED Hsi, MJ Maurer, LD Pederson, ... Journal of clinical oncology 37 (21), 1790, 2019 | 355 | 2019 |
| Long-term clinical outcomes of tisagenlecleucel in patients with relapsed or refractory aggressive B-cell lymphomas (JULIET): a multicentre, open-label, single-arm, phase 2 study SJ Schuster, CS Tam, P Borchmann, N Worel, JP McGuirk, H Holte, ... The Lancet Oncology 22 (10), 1403-1415, 2021 | 304 | 2021 |
| Clinical course of oxaliplatin-induced neuropathy: results from the randomized phase III trial N08CB (Alliance) DR Pachman, R Qin, DK Seisler, EML Smith, AS Beutler, LE Ta, JM Lafky, ... Journal of Clinical Oncology 33 (30), 3416, 2015 | 295 | 2015 |
| Postibrutinib outcomes in patients with mantle cell lymphoma P Martin, K Maddocks, JP Leonard, J Ruan, A Goy, N Wagner-Johnston, ... Blood, The Journal of the American Society of Hematology 127 (12), 1559-1563, 2016 | 276 | 2016 |
| A phase 1 study of the PI3Kδ inhibitor idelalisib in patients with relapsed/refractory mantle cell lymphoma (MCL) BS Kahl, SE Spurgeon, RR Furman, IW Flinn, SE Coutre, JR Brown, ... Blood, The Journal of the American Society of Hematology 123 (22), 3398-3405, 2014 | 269 | 2014 |
| DYNAMO: a phase II study of duvelisib (IPI-145) in patients with refractory indolent non-Hodgkin lymphoma IW Flinn, CB Miller, KM Ardeshna, S Tetreault, SE Assouline, J Mayer, ... Journal of Clinical Oncology 37 (11), 912-+, 2019 | 253 | 2019 |
| Reduced-intensity transplantation for lymphomas using haploidentical related donors versus HLA-matched sibling donors: a Center for International Blood and Marrow Transplant … N Ghosh, R Karmali, V Rocha, KW Ahn, A DiGilio, PN Hari, V Bachanova, ... Journal of Clinical Oncology 34 (26), 3141, 2016 | 245 | 2016 |
| Idelalisib, a selective inhibitor of phosphatidylinositol 3-kinase-δ, as therapy for previously treated indolent non-Hodgkin lymphoma IW Flinn, BS Kahl, JP Leonard, RR Furman, JR Brown, JC Byrd, ... Blood, The Journal of the American Society of Hematology 123 (22), 3406-3413, 2014 | 242 | 2014 |
| Outcomes of transformed follicular lymphoma in the modern era: a report from the National LymphoCare Study (NLCS) ND Wagner-Johnston, BK Link, M Byrtek, KL Dawson, J Hainsworth, ... Blood, The Journal of the American Society of Hematology 126 (7), 851-857, 2015 | 221 | 2015 |
| A phase 2 multicenter study of lenalidomide in relapsed or refractory classical Hodgkin lymphoma TA Fehniger, S Larson, K Trinkaus, MJ Siegel, AF Cashen, KA Blum, ... Blood, The Journal of the American Society of Hematology 118 (19), 5119-5125, 2011 | 219 | 2011 |
| Efficacy and safety of idelalisib in combination with ofatumumab for previously treated chronic lymphocytic leukaemia: an open-label, randomised phase 3 trial JA Jones, T Robak, JR Brown, FT Awan, X Badoux, S Coutre, ... The Lancet Haematology 4 (3), e114-e126, 2017 | 212 | 2017 |
| A phase 2/3 multicenter, randomized, open-label study to compare the efficacy and safety of lenalidomide versus investigator's choice in patients with relapsed or refractory … MS Czuczman, M Trněný, A Davies, S Rule, KM Linton, ... Clinical cancer research 23 (15), 4127-4137, 2017 | 161 | 2017 |
| CAL-101, an isoform-selective inhibitor of phosphatidylinositol 3-kinase P110δ, demonstrates clinical activity and pharmacodynamic effects in patients with relapsed or … RR Furman, JC Byrd, JR Brown, SE Coutre, DM Benson Jr, ... Blood, The Journal of the American Society of Hematology 116 (21), 55-55, 2010 | 150 | 2010 |
| Clinical safety and activity in a phase 1 study of CAL-101, an isoform-selective inhibitor of phosphatidylinositol 3-kinase P110δ, in patients with relapsed or refractory non … B Kahl, JC Byrd, IW Flinn, N Wagner-Johnston, S Spurgeon, ... Blood 116 (21), 1777, 2010 | 146 | 2010 |
